Theranova, LLC

TheraNova, LLC operates as a venture studio and incubator, specializing in the end-to-end development of medical devices. The firm takes medical innovations from initial concept through clinical trials, regulatory approval, and ultimately to market commercialization. Its methodology emphasizes a rapid, capital-efficient R&D model that integrates comprehensive engineering capabilities, intellectual property strategies, and regulatory expertise to create practical solutions.

The enterprise was established by a team of medical and entrepreneurial leaders, including CEO Daniel Burnett, CMO Shane Mangrum, and CSO Eran Steinberg. Dr. Mangrum is explicitly noted as a founding partner, contributing clinical insight as a board-certified physician. Dr. Burnett, an MD/MBA, has been involved in the firm's numerous spinouts since 2006, while Steinberg brings extensive experience as a founder with a strong background in regulatory processes. Their collective insight focused on streamlining the complex medical device development lifecycle.

TheraNova targets large markets with unmet medical needs, developing solutions designed to improve patient outcomes, broaden healthcare access, and reduce costs for patients and payers. The company’s vision is to continually foster the creation of impactful medical technologies by incubating and spinning out new ventures, guiding them through the entire innovation pathway to address critical healthcare challenges with advanced, well-vetted devices.

TheraNova, LLC is a San Francisco–based medical device venture studio and incubator that develops and spins out medtech companies, with a focus on creating capital-efficient device programs that move from concept through clinical trials, regulation and commercialization[1].TheraNova says it has spun out ~20 companies, raised more than $400M for portfolio companies, obtained multiple FDA clearances and 120+ US patents, and run 30+ clinical trials while also raising >$35M in government grants[1].

High-Level Overview

• Mission: TheraNova’s stated mission is to improve patient outcomes, expand access to care, and reduce costs by rapidly developing medical devices and incubating startups in a shared-services model[3][1].
  - Investment / operating philosophy: TheraNova operates as a venture-studio/incubator focused on a *highly capital-efficient*, end‑to‑end medtech development pipeline that combines engineering, regulatory, clinical, IP and reimbursement expertise to de‑risk and accelerate device programs[1].
  - Key sectors: Primarily medical devices and diagnostics across clinical markets with “large unmet needs,” including enteral feeding systems and other hospital/clinical technologies (example SBIR project: an enteral feeding system with tip‑location monitoring)[6][1].
  - Impact on the startup ecosystem: TheraNova acts as an operator‑led incubator that spins out companies, attracts grant and venture funding for portfolio ventures, and partners with institutions (e.g., UCSF Surgical Innovations) to funnel academic innovation into commercial device programs[3][1].

Origin Story

• Founding and leadership: Public profiles list Dan (Daniel) Burnett, M.D., as founder and CEO of TheraNova, which was founded in the mid‑2000s (RocketReach lists 2006)[2][3].
  - How the idea emerged: TheraNova was built around a “triple aim” — improve outcomes, expand access, and reduce costs — and structured as a shared R&D/incubator to overcome common medtech barriers (regulatory, clinical trials, reimbursement) through an integrated team of engineering, regulatory and clinical experts[3][1].
  - Early traction / pivotal moments: The firm reports early success in spinning out multiple companies, securing FDA approvals/clearances (PMA and 510(k)), filing many patents, conducting clinical trials, and winning government grant funding including SBIR awards for specific device projects[1][6].

Core Differentiators

• Integrated venture-studio model: Combines concept, engineering, clinical study execution, regulatory strategy and reimbursement planning under one roof to move devices faster and more efficiently than an ad hoc approach[1].
  - Operational engineering depth: In‑house capabilities across mechanical, electrical, software, rapid prototyping and manufacturing that support device development from prototype to production[1].
  - Regulatory and clinical track record: Public claims of multiple FDA clearances/approvals and dozens of completed clinical trials provide demonstrable regulatory experience for spinouts[1].
  - Grant and fundraising success: Experience securing government grants (SBIR) and helping portfolio companies raise institutional capital (claimed >$400M raised to date)[1][6].
  - Network & partnerships: Active partnerships with academic incubators (example: UCSF Surgical Innovations) that provide deal flow and clinical collaboration[3].

Role in the Broader Tech Landscape

• Trend alignment: TheraNova rides the ongoing trend toward specialized venture‑studio/incubator models in medtech that centralize scarce development expertise and reduce per‑project cost and time to market[1].
  - Timing and market forces: Rising demand for devices that lower inpatient costs and expand access, combined with more available non‑dilutive funding (SBIR) and active medtech venture capital, make a capital‑efficient studio attractive to founders and investors[6][1].
  - Influence: By spinning out companies and shepherding regulatory approvals, TheraNova helps translate academic and clinical ideas into commercial products, increasing the throughput of medtech innovations into the healthcare system[3][1].

Quick Take & Future Outlook

• What’s next: Expect continued spinning out of device companies, pursuit of SBIR/grant opportunities, and partnerships with academic medical centers to source early‑stage device concepts[1][6][3].
  - Trends that will shape them: Increased emphasis on reimbursement strategy, value‑based care, and integration of digital health/software into devices will influence which projects they pursue and how they structure spinouts[1].
  - Potential evolution: If they maintain their claimed regulatory and fundraising track record, TheraNova could position itself as a leading medtech studio that reliably de‑risks early device programs for downstream acquirers and investors[1].

Quick take: TheraNova is an operator‑driven medtech incubator/venture studio focused on capital‑efficient device development and commercialization, leveraging deep engineering, regulatory and clinical capabilities to spin out startups and accelerate medtech translation[1][3][6].